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ARTICLE OPEN
The FANCM:p.Arg658* truncating variant is associated with
risk of triple-negative breast cancer
Gisella Figlioli et al.
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes
BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has
been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer
(TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for
association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2.
These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived
immortalized ﬁbroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with
increased risk of ER-negative disease and TNBC (OR= 2.44, P= 0.034 and OR= 3.79; P= 0.009, respectively). In a country-restricted
analysis, we conﬁrmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with
ER-negative breast cancer risk (OR= 1.96; P= 0.006). The functional results indicated that all three variants were deleterious
affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we
conﬁrmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC
subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the
gene. Cell sensitivity to olaparib exposure, identiﬁes a possible therapeutic option to treat FANCM-associated tumors.
npj Breast Cancer            (2019) 5:38 ; https://doi.org/10.1038/s41523-019-0127-5
INTRODUCTION
The genetic architecture of inherited breast cancer is complex and
involves germline pathogenic variants in high and moderate-risk
genes and polygenetic factors. The major high-penetrance breast
cancer risk genes include BRCA1 and BRCA2, which are key factors
in the DNA double-strand break repair through homologous
recombination (HR) and in the inter-strand crosslink (ICL) repair as
a part of the Fanconi Anemia (FA) pathway.1,2 Recently, based on a
prospective cohort of families carrying BRCA1 or BRCA2 patho-
genic variants, the average cumulative risk by age 80 was
estimated to be 72% and 69% for carriers of BRCA1 and BRCA2
pathogenic variants, respectively.3 PALB2 has been previously
considered a moderate-risk gene, but the latest estimate of about
44% lifetime risk associated with pathogenic variants may raise
this gene to the high-risk group.4 Pathogenic variants in
moderate-penetrance genes ATM and CHEK2 are also associated
with breast cancer, conferring a 20% average lifetime risk.5,6
Recently, BARD1, RAD51D, BRIP1, and RAD51C have been proposed
as risk factors for triple-negative breast cancer (TNBC) with BARD1
and RAD51D conferring high risk, and BRIP1 and RAD51C
associated with moderate risk.7 Thus, the risk associated with
pathogenic variants in each gene may vary by breast tumor
subtype.
Many of the BRCA/FA pathway genes when altered by biallelic
mutations cause FA disease. The FANCM gene (FA complementa-
tion group M, OMIM #609644) encodes for a translocase, which is
a member of the BRCA/FA molecular pathway but has been
recently disqualiﬁed as a disease-causing factor for FA.8,9 Some
protein-truncating variants in the FANCM gene were described as
moderate breast cancer risk factors with a greater risk of TNBC. In
the Finnish population, FANCM:c.5101 C > T (p.Gln1701*,
rs147021911) is relatively frequent and was reported to be
associated with breast cancer with odds ratio (OR) of 1.86 with
95% conﬁdence intervals (CIs)= 1.26–2.75. A larger effect was
observed in familial cases (OR= 2.11; 95% CI= 1.43–3.32), for
estrogen receptor-negative (ER-negative) breast cancer (OR=
2.37; 95% CI= 1.37–4.12) and for TNBC (OR= 3.56; 95% CI=
1.81–6.98).10 We showed an increased risk (OR= 3.93; 95% CI=
1.28–12.11) of the FANCM:c.5791 C > T (rs144567652) truncating
variant using familial cases and controls. In vitro analysis showed
that this variant causes the skipping of the FANCM exon 22 and
the creation of a downstream stop codon (p.Gly1906Alafs12*).11
However, in the present study we refer to the FANCM:c.5791 C > T
base change as to FANCM:p.Arg1931*, which is the conventional
amino acid annotation (consistent with the stop codon creation
according to genetic code). The FANCM:p.Arg1931* was also found
to be associated with TNBC risk in the Finnish population (OR=
5.14; 95% CI= 1.65–16.0).12 A burden analysis of truncating
variants discovered by a re-sequencing analysis of the entire
FANCM coding region in German cases and controls conﬁrmed
that FANCM pathogenic variants had a particularly high risk for
TNBC (OR= 3.75; 95% CI= 1.0–12.85).13
To study the effect of FANCM on breast cancer risk further, we
tested three recurrent truncating variants FANCM:p.Arg658*, p.
Gln1701*, and p.Arg1931*, within the OncoArray Consortium, a
collaboration of consortia established to discover germline
genetic variants predisposing to different human cancers (e.g.,
breast, colon, lung, ovary, endometrium and prostate cancers).14
These three variants were tested for association with breast cancer
risk in 67,112 breast cancer cases, 53,766 controls, and 26,662
carriers of pathogenic variants in BRCA1 or BRCA2. We also studied
the functional effect of these three variants after their lentiviral
transduction into a FANCM−/− patient-derived cell line in which
*email: paolo.peterlongo@ifom.eu. A full list of authors and their afﬁliations appears at the end of the paper.
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we measured survival and chromosome fragility after exposure to
diepoxybutane (DEB) or the poly (ADP-ribose) polymerase
inhibitor (PARPi) olaparib.
RESULTS
Case-control analyses
We analyzed the association of three FANCM truncating variants,
p.Arg658*, p.Gln1701*, and p.Arg1931*, with breast cancer risk for
each variant separately and using a burden analysis. We tested
67,112 invasive breast cancer cases and 53,766 controls collected
by the Breast Cancer Association Consortium (BCAC, http://bcac.
ccge.medschl.cam.ac.uk/) and 26,662 carriers of BRCA1 or BRCA2
pathogenic variants collected by the Consortium of Investigators
of Modiﬁers of BRCA1/2 (CIMBA, http://cimba.ccge.medschl.cam.
ac.uk/), of whom 13,497 were affected with breast cancer and
13,165 were unaffected.
In the BCAC dataset we assessed the breast cancer risk
associated with the FANCM variants in a primary overall analysis
and in a restricted analysis including only countries in which the
variant carrier frequencies were higher than the median of
the frequencies. In these analyses we tested association with the
variants in all available invasive breast cancer cases or in the ER-
positive, ER-negative and TNBC subgroups (Table 1). In the overall
analysis, no evidence of association was observed, either with the
presence of any FANCM variant or with any of the three variants
individually. However, FANCM:p.Arg658* showed a higher hetero-
zygote frequency in ER-negative breast cancer cases (0.093%) than
in controls (0.035%) with a greater than two-fold increased breast
cancer risk (OR= 2.44, 95% CI= 1.12–5.34, P= 0.034). When only
TNBC cases were considered, the association was stronger (OR=
3.79, 95% CI= 1.56–9.18, P= 0.009). No association with ER-
negative breast cancer or TNBC was seen for p.Gln1701* or p.
Arg1931* or for all mutations combined (Table 1). In the country-
restricted analyses, we conﬁrmed the association found for p.
Arg658* with risk of ER-negative disease and TNBC (OR= 2.31,
95% CI= 1.05–5.07, P= 0.047 and OR= 3.56, 95% CI= 1.46–8.69,
P= 0.011, respectively). The restricted set also provided evidence
for an association between p.Arg1931* and ER-negative subgroup
(OR= 1.96, 95% CI= 1.24–3.10, P= 0.006), though not for TNBC.
No signiﬁcant association was observed for p.Gln1701* with either
subgroups (Table 1).
Analyses of carriers of BRCA1 or BRCA2 pathogenic variants
We found no evidence of associations for FANCM:p.Arg658*, p.
Gln1701*, and p.Arg1931* truncating variants with breast cancer
risk in carriers of BRCA1 or BRCA2 pathogenic variants included in
CIMBA (Supplementary Table 1). The p.Arg658* was detected with
approximately four-fold higher frequencies in the BRCA1 affected
individuals (0.063%) in comparison to the unaffected (0.013%),
and in the BRCA2 affected individuals (0.071%) in comparison to
the unaffected (0.019%). Consistently, hazard ratios (HRs) above
two were estimated for BRCA1 (HR= 2.4, 95% CI= 0.52–11.12) and
for BRCA2 (HR= 2.13, 95% CI= 0.41–11.14) pathogenic variant
carriers. The frequencies of p.Gln1701* and p.Arg1931* were not
increased in affected versus unaffected individuals carrying BRCA1
or BRCA2 pathogenic variants (Supplementary Table 1).
Functional studies
We tested the functional effect of FANCM:p.Arg658*, p.Gln1701*,
and p.Arg1931* on DNA repair using genetic complementation
assays (Fig. 1). These assays were based on the EGF280 cell line
derived from immortalized ﬁbroblasts from a patient who lacked
the FANCM protein due to a homozygous c.1506_1507insTA (p.
Ile503*, rs764743944) truncating variant.8 Complemented
FANCM−/− cells were tested for sensitivity to DEB and olaparib
Table 1. Single-variant and burden analyses of FANCM:p.Arg658*, p.
Gln1701* and p.Arg1931* truncating variants in overall and country-
restricted invasive breast cancer cases and controls
Overall
Subgroup Carriers Non-carriers Freq % OR 95% CI P
FANCM:p.Arg658*
Controls 19 53,717 0.035 NA
All cases 31 67,038 0.046 1.26 0.71–2.25 0.430
ER-positive 19 44,516 0.043 1.15 0.61–2.20 0.670
ER-negative 10 10,750 0.093 2.44 1.12–5.34 0.034
TNBC 7 4794 0.146 3.79 1.56–9.18 0.009
FANCM:p.Gln1701*
Controls 122 53,635 0.229 NA
All cases 155 66,951 0.232 1.09 0.85–1.38 0.798
ER-positive 97 44,467 0.218 1.02 0.78–1.34 0.893
ER-negative 21 10,748 0.204 0.97 0.61–1.56 0.369
TNBC 10 4794 0.229 1.09 0.57–2.10 0.149
FANCM:p.Arg1931*
Controls 96 53,633 0.179 NA
All cases 116 66,968 0.173 1.05 0.80–1.38 0.731
ER-positive 74 44,467 0.166 1.02 0.75–1.38 0.920
ER-negative 27 10,742 0.251 1.52 0.98–2.35 0.070
TNBC 10 4795 0.208 1.29 0.67–2.50 0.461
All variantsa
Controls 237 53,455 0.443 NA
All cases 302 66,736 0.452 1.02 0.86–1.21 0.823
ER-positive 190 44,323 0.427 0.96 0.79–1.16 0.698
ER-negative 58 10,700 0.548 1.23 0.92–1.64 0.154
TNBC 27 4773 0.583 1.32 0.89–1.95 0.167
Country-restricted
Subgroup Carriers Non-carriers Freq % OR 95% CI P
FANCM:p.Arg658*
Controls 19 48,887 0.039 NA
All cases 31 59,540 0.052 1.23 0.69–2.20 0.478
ER-positive 19 39,453 0.048 1.12 0.59–2.15 0.722
ER-negative 10 9613 0.104 2.31 1.05–5.07 0.047
TNBC 7 4283 0.163 3.56 1.46–8.69 0.011
FANCM:p.Gln1701*
Controls 120 48,506 0.249 NA
All cases 152 58,919 0.259 1.08 0.85–1.38 0.813
ER-positive 96 38,892 0.246 1.02 0.77–1.34 0.895
ER-negative 21 9558 0.230 0.97 0.60–1.56 0.368
TNBC 10 4197 0.261 1.09 0.56–2.10 0.150
FANCM:p.Arg1931*
Controls 77 34,988 0.220 NA
All cases 93 37,903 0.245 1.14 0.84–1.54 0.396
ER-positive 59 25,274 0.233 1.09 0.77–1.53 0.632
ER-negative 25 5920 0.421 1.96 1.24–3.10 0.006
TNBC 10 2614 0.381 1.77 0.91–3.45 0.116
All variantsb
Controls NA
All cases NA
ER-positive NA
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by measuring cell survival and chromosome fragility. The FANCM
protein was not detectable in the EGF280 ﬁbroblasts. The
transduction of these cells with lentiviral vectors carrying wild-
type (wt) FANCM cDNA and cDNAs harboring FANCM:p.Gln1701*
and p.Arg1931* variants produced, as expected, different C-
terminal truncated forms of FANCM. In the EGF280 cells
transduced with FANCM:p.Arg658* no visible band was observed
on western blot (Fig. 1a and Supplementary Fig. 1). As we lack
information on the epitope recognized by the antibody, we could
not determine whether the p.Arg658*-derived truncated protein
was unstable or if the epitope was lost due to the truncation. We
therefore analyzed the mRNA expression of FANCM:p.Arg658* by
reverse transcription and digestion of the PCR-ampliﬁed cDNAs.
The c.1972C > T base substitution causing the p.Arg658* variant
was expected to abolish a digestion site for the restriction enzyme
TseI present in the wt sequence. TseI-digestion of wt and mutated
cDNAs clearly indicated the presence of a mutated mRNA product
in the EGF280 cells transduced with FANCM:p.Arg658* (Fig. 1b and
Supplementary Fig. 1).
In the DEB sensitivity-based assay (Fig. 1c), the EGF280 patient-
derived cell line showed a high-sensitivity phenotype, that was
rescued by expression of the wt FANCM. EGF280 cells expressing
FANCM:p.Arg658* failed to rescue DEB sensitivity and showed
survival rates overlapping with those of the native EGF280 cells. In
comparison, cells expressing FANCM:p.Gln1701* and p.Arg1931*
variants showed an intermediate phenotype with survival rates
signiﬁcantly higher than those of EGF280 cells, though signiﬁ-
cantly lower than those of the cells expressing wt FANCM (Fig. 1c
and Supplementary Table 2). These results were conﬁrmed in the
chromosome fragility tests where the number of chromatidic
breaks in cells harboring p.Gln1701* or p.Arg1931* variants was
statistically lower than that of EGF280 cells or cells expressing the
p.Arg658* and statistically higher than that of cells expressing wt
FANCM (Fig. 1d). In the olaparib sensitivity-based assay, the
survival rates of the cell lines transduced with the three FANCM
truncating variants were not statistically different. Only at higher
olaparib concentrations (>5000 nM) the survival rates of these cell
lines were signiﬁcantly lower than that of the wt FANCM cells and
higher than that of the EGF280 cells (Fig. 1e and Supplementary
Table 3).
DISCUSSION
In this study we investigated the association of the three recurrent
FANCM truncating variants p.Arg658*, p.Gln1701*, and p.Arg1931*,
with breast cancer risk overall and by tumor subtype. While in
non-Finnish Europeans these are the three most common FANCM
truncating variants, their carrier frequency is low being 0.033, 0.21
and 0.21%, respectively (https://gnomad.broadinstitute.org/).15 We
conducted large case-control studies in 67,112 unselected breast
cancer cases, 53,766 controls, and 26,662 carriers of BRCA1 or
BRCA2 pathogenic variants. Furthermore, we performed functional
analyses based on a patient-derived FANCM−/− cell line trans-
duced with vectors carrying the three FANCM variants and tested
for sensitivity to DEB or olaparib. Our genetic data suggest that
FANCM:p.Arg658* is a risk factor for ER-negative and TNBC
subtypes with statistically signiﬁcant ORs of 2.44 and 3.79,
respectively. These associations were conﬁrmed when we
restricted the analyses to countries with higher carrier frequencies.
In these restricted analyses we also found that the p.Arg1931* was
associated with breast cancer risk in the ER-negative subtype with
statistically signiﬁcant OR= 1.96. (Table 1). These data, together
with previously published genetic studies,10–13 conﬁrm that
FANCM truncating variants are risk factors for breast cancer, with
a stronger association for the ER-negative and TNBC subtypes. Our
functional data, obtained in a background of a FANCM null cell
line, support these ﬁndings showing that all three truncating
variants were deleterious; hence, it is expected that, in the
heterozygous state, any of these FANCM variants have partial
activity. In the functional tests, we also observed that olaparib had
a greater effect on survival of the cells harboring any of the
FANCM:p.Arg658*, p.Gln1701*, or p.Arg1931* variants with respect
to that on EGF280 cells complemented with wt FANCM (Fig. 1e).
As this is consistent with previous results,16 PARP1 inhibition
might be a possible therapeutic approach to treat patients with
breast tumors associated with germline FANCM pathogenic
variants. On the contrary, the DEB sensitivity assays showed that
FANCM:p.Arg658*, is associated with a stronger impairment of
DNA repair activity, compared to p.Gln1701* and p.Arg1931*,
possibly reﬂecting the position of protein truncation (Fig. 1c, d).
FANCM encodes for a key protein of the upstream FA/BRCA
pathway mediating the assembly of the FA core complex. This
protein is 2048 AA long, possesses in its N-terminal region an
intrinsic ATP-dependent DNA translocase activity and, with its
central region, recognizes the Bloom’s complex, which is also
involved in the DNA HR repair. By interacting with its C-terminal
binding partner, the FA associated protein 24 (FAAP24), the
FANCM protein brings to sites of ICL DNA lesions the FA and the
Bloom’s complexes initiating HR repair17 (Fig. 2). We studied
FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* in the same
genetic FANCM−/− background and showed that, after exposure
to DEB, the N-terminal FANCM:p.Arg658* had a statistically
stronger effect on cell survival and chromosome stability
(presumably due to less efﬁcient DNA repair activity) than did p.
Gln1701* and p.Arg1931*. This also suggests that in human living
cells the FANCM:p.Arg658* variant might impair DNA repair more
severely than p.Gln1701* and p.Arg1931*. We have shown that
in vitro both the p.Gln1701*- and the p.Arg1931*-derived FANCM
proteins are expressed and that the p.Arg658*-mRNA is tran-
scribed (Fig. 1a, b). An N-terminus fragment including the ﬁrst 422
AA of FANCM was shown to be stable when expressed in human
cell lines,17 thus supporting the possibility that the FANCM:p.
Arg658*-derived protein may also be expressed and stable. Hence,
we hypothesize that the observed difference in survival and
chromosome fragility of cells treated with DEB may be attributable
to the diverse residual function of the different truncated forms of
FANCM. In fact, the p.Gln1701*- and the p.Arg1931*-derived forms
are expected to lose the interaction with FAAP24, but to retain the
ability of binding other FANCM interacting proteins. Hence, our
data suggest that the lack of interaction between FANCM and
FAAP24 has a less severe impact on the DNA damage response
than when protein truncation occurs upstream the FANCM
domains AA 687–1104 and AA 1027–1362 mediating the
interaction with the FA core complex and the Bloom’s complex,
respectively.
Previously published genetic and clinical data support our
hypothesis of a position effect. FANCM pathogenic variants were
shown to be associated with a moderate risk of developing high-
grade serous epithelial ovarian cancer, but p.Arg1931* appeared
to confer a lower risk.18 Moreover, ﬁve female breast cancer
Table 1 continued
Country-restricted
Subgroup Carriers Non-carriers Freq % OR 95% CI P
ER-negative NA
TNBC NA
In bold are indicated the statistically signiﬁcant results
Freq frequency, OR odds ratio CI conﬁdence interval, P P-value, TNBC triple-
negative breast cancer, NA not applicable
aThe burden analyses were performed by univariate logistic regression
bThese analyses were not possible in the country-restricted cases and
controls as different countries were included for each variant. P-values
were from Pearson chi-squared test
G. Figlioli et al.
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Fig. 1 Functional studies of the FANCM:p.Arg658*, p.Gln1701* and p.Arg1931* truncating variants using the patient-derived FANCM−/−
EGF280 cell line. a Western blot showing the FANCM expression in EGF280 cells complemented with lentiviral vectors harboring the three
different variants. Bands corresponding to truncated FANCM protein were visible for EGF280+ p.Gln1701* and p.Arg1931*, and no bands
were present for the EGF280+ p.Arg658*. b Study of the expression of the FANCM protein in EGF280+ p.Arg658*. The c.1972C > T base
substitution, causing the p.Arg658* variant abrogates a digestion site for the restriction enzyme TseI that is present in the wild-type (wt) cDNA
sequence. Total RNA was extracted from EGF280+wtFANCM and from the EGF280+ p.Arg658* and subjected to reverse transcription. PCR-
ampliﬁed cDNA products were digested with TseI. Digested and undigested cDNAs were loaded. In the ﬁrst two lanes are shown bands of
386 bp corresponding to uncut wt cDNA, and bands of 257 and 129 bp corresponding to cut wt cDNA. In next two lanes bands of 386 bp
indicate that p.Arg658* cDNA was not cut due to the c.1972C > T base substitution abrogating the TseI site. In the two lanes after the
molecular weight marker (M) undigested and digested products of the two previous PCR products were mixed 1:1 and loaded as a control. c
Analysis of diepoxybutane (DEB) sensitivity on cell survival. The EGF280 cells expressing p.Arg658* are signiﬁcantly more sensitive to DEB than
the cells expressing p.Gln1701* or p.Arg1931* (P-values from Tukey’s range test are reported in Supplementary Table 4). EGF280 and EGF280+
wtFANCM are used as controls (N= 3; error bars: standard deviation). d Chromosome fragility induced by DEB treatment (100 ng/ml). Here, the
chromatidic break patterns of the cells expressing wt FANCM, of the cells harboring p.Gln1701* or p.Arg1931* variants, and of the native
EGF280 cells or the cells expressing p.Arg658* were statistically different. (P-values from chi-squared test; N= 2). e Analysis of cellular
sensitivity to olaparib. Contrarily to what we observed in the DEB sensitivity assays, survival rates of the different complemented cell lines
were apparently not different. Human ﬁbroblasts (BRCA2−/−) were homozygous for the c.469 A > T (p.Lys157*) truncating variant and were
used as a positive control. (P-values from Tukey’s range test are reported in Supplementary Table 5; N= 3; error bars: standard deviation). All
blots derive from the same experiment and were processed in parallel
G. Figlioli et al.
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probands carrying homozygous FANCM truncating variants were
recently described.9 Three of these, two homozygous for p.
Gln1701*, and one for p.Arg1931*, developed breast cancer at age
52 years or later and their cells did not demonstrate chromosome
fragility. The other two probands were homozygous for p.Arg658*
and developed early-onset breast cancer (at age 29 and 32); in
addition, one developed several cancers, and the other demon-
strated chromosomal fragility.9
Due to the rarity of the studied mutations in most populations,
estimation of the risks is challenging. Preferably, the cases should
be examined in comparison to geographically, ethnically and
genetically matched controls. In the Finnish population, p.
Gln1701* and p.Arg1931* are reported with carrier frequency of
1.62% and of 0.92%, respectively (https://gnomad.broadinstitute.
org/).15 Case-control studies based on the Finnish population
showed a strong statistical evidence of association of p.Gln1701*
with ER-negative disease, with OR of 2.37 (95% CI= 1.37–4.12, P=
0.0021), and with TNBC with ORs of 3.56 (95% CI= 1.81–6.98, P=
0.0002),10 while p.Arg1931* was found associated with TNBC with
an OR of 5.14 (95% CI= 1.65–16.0, P= 0.005).12 However, as our
95% CI of risk estimates for TNBC included odds ratios of 2 for
both the latter mutations, the published and our results are not
mutually exclusive. Risk estimates associated with rare variants
may depend on their frequency and the genetic background of
the population studied. Hence, pooling the data from multiple
outbred and admixed populations as it was done in the present
study, may yield different risk estimates than those derived from
geographically, ethnically and genetically matched controls, as in
the Finnish studies. Indeed, it would have been interesting to test
the FANCM variant position effect in the Finnish population, but
unfortunately the p.Arg658* is very rare if not absent in this
population (https://gnomad.broadinstitute.org/).15
Recent attempts to identify novel, high- to moderate-risk breast
cancer-predisposing genes have not been particularly fruitful.
However, a few genes have emerged as potential risk factors for
ER-negative disease and TNBC, with FANCM, BRIP1, and RAD51C
being among those suggested to confer moderate risk of these
subtypes. Other predisposing genes increasing the risk of ER-
negative and TNBC may also exist. Hence, further gene discovery
efforts should take into consideration that risk-associated variants
may be associated with speciﬁc tumor subtypes and/or variation
in risk may depend on the variant position. In addition, we provide
evidence that lack of FANCM protein and truncating variants
identiﬁed in breast cancer patients are associated with increased
sensitivity to the PARPi olaparib suggesting a therapeutic
opportunity to treat FANCM-associated breast tumors that
warrants further investigation. The PARPi sensitivity test may also
prove useful for preclinical investigation of further truncating or
missense FANCM variants.
In summary, we have shown that FANCM:p.Arg658* is
associated with risk of ER-negative breast cancer and TNBC. The
outcomes of functional assays testing the DNA repair efﬁciency in
complemented human cells support the hypothesis that breast
cancer risk may be greater for N-terminal than C-terminal FANCM
truncating variants. Further genetic studies and meta-analyses are
warranted to derive more precise risk estimates for the different
FANCM variants.
METHODS
Study participants
The individuals included in this study were women of genetically
conﬁrmed European ancestry who were originally ascertained in 73 case-
control studies from 19 countries participating in the BCAC or in 59 studies
enrolling BRCA1 or BRCA2 pathogenic variants carrier from 30 countries
participating in the CIMBA.
Ethics
All participating studies, listed in Supplementary Table 4 and Supplemen-
tary Table 5, were approved by their ethics review boards and followed
national guidelines for informed consent. However, due to the retro-
spective nature of the majority of the studies, not all participant individuals
have provided written informed consent to take part in the present
analysis. The Milan Breast Cancer Study Group (MBCSG) was approved by
ethics committee from Istituto Nazionale dei Tumori di Milano and Istituto
Europeo di Oncologia, in Milan.
The BCAC studies contributed 67,112 invasive breast cancer cases and
53,766 controls. The majority of these studies were population-based,
hospital-based or case-control studies nested within population-based
cohorts (86%); few were family-clinic-based studies (14%; Supplementary
Table 4). For each study subject, information on the disease status and the
age at diagnosis or at interview were provided. Data on lifestyle risk factors
were available for most subjects and clinical and pathological data were
available for most cases. All these data were incorporated in the BCAC
dataset (version 10). A total of 44,565 (66%) cases were ER-positive, 10,770
(16%) were ER-negative, and 4,805 (7%) were TNBC; 13,743 (20%) had a
positive ﬁrst-degree family history of breast cancer.
The CIMBA studies contributed 15,679 carriers of a pathogenic BRCA1
variant and 10,983 carriers of a pathogenic BRCA2 variant to this analysis
(Supplementary Table 5). Nearly all (98%) of these carriers were ascertained
through cancer genetic clinics; few carriers were recruited by population-
based sampling of cases or by community recruitment. In some instances,
multiple members of the same family were included. For each pathogenic
variant carrier, the information on the type of the BRCA1 or BRCA2 variant,
disease status, and censoring variables (see below, Statistical analyses)
were collected and included in the CIMBA database.
Genotyping
Genotyping of FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* truncating
variants was conducted using a custom-designed Illumina genotyping
array (the “OncoArray”, Illumina, Inc. San Diego, CA, USA) at six
independent laboratories. To ensure consistency of the genotype data,
all laboratories used the same genotype-clustering ﬁle and genotyped the
same set of reference-samples selected from the HapMap project. Samples
with a call rate <95% and those with heterozygosity <5% or >40% were
excluded. Further details of the genotype-calling and quality control have
been described previously.14 The cluster plots of the three FANCM
truncating variants were curated manually to conﬁrm the automatic calls
(Supplementary Fig. 2).
Statistical analyses
The BCAC data were analyzed to test the association between FANCM:p.
Arg658*, p.Gln1701*, and p.Arg1931* and breast cancer risk. Logistic
regression analyses were performed to estimate ORs with 95% CIs for
variant carriers versus non-carriers, adjusting for country and the ﬁrst ten
principal components, as previously described.19 P-values were calculated
by applying the likelihood ratio test (LRT) comparing the model containing
the variant carrier status as a covariate to a model without the variant
carrier status. The primary analyses were performed including all invasive
breast cancer cases and controls and subgrouping cases based on tumor
hormonal status. We then performed a country-restricted analysis
Fig. 2 Schematic diagram of the 2,048 amino acid long FANCM protein. The functional or binding domains (BD) are indicated in black and as
reported in Deans and West, 2009. The position of the three FANCM truncating variants c.1972C > T (p.Arg658*), c.5101 C > T (p.Gln1701*) and
c.5791 C > T (p.Arg1931*) is also shown
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including the 50% of the countries with the higher variant carrier
frequencies. Speciﬁcally, we included only countries in which the carrier
frequencies in cases and controls combined were higher than the median
of the carrier frequencies observed in all countries. Median frequencies
were 0.007, 0.114 and 0.163 for p.Arg658*, p.Gln1701* and p.Arg1931*
carriers, respectively.
The CIMBA data were analyzed to evaluate the association between
each FANCM truncating variant and breast cancer risk in carriers of BRCA1
or BRCA2 pathogenic variant. A survival analyses framework was applied.
Brieﬂy, each variant carrier was followed from the age of 18 years until the
ﬁrst breast cancer diagnosis, or censored as unaffected at ovarian cancer
diagnosis, bilateral prophylactic mastectomy, or age at last follow-up. The
analyses were performed by modelling the retrospective likelihood of the
observed genotypes conditional on the disease phenotype as detailed
previously.20 All analyses were stratiﬁed for country. The per-allele hazard
ratio (HR), 95% CIs were estimated separately for each variant. A score test
was used to derive P-values for the associations. The analyses of the BCAC
data were performed using STATA version 15 (StataCorp LLC, College
Station, Texas, USA). The analyses of the CIMBA data were carried out using
custom-written code in Python and Fortran. All statistical tests were two-
sided and P-values <0.05 were considered statistically signiﬁcant.
Cell lines, plasmids, and lentiviral particles production and
transduction
The immortalized patient-derived FANCM−/− cell line EGF2808 was
transduced with pLenti CMV rtTA3 Blast, a gift from E. Campeau (Addgene
plasmid #26429). The doxycycline-inducible lentiviral vector pLVX-TRE3G-
FANCM, a gift from N. Ameziane (Vrije Universiteit Medical Center,
Amsterdam) was mutated by site-directed mutagenesis using the
QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies)
and the following PAGE puriﬁed mutagenic primers. FANCM c.1972C > T
primer 1: 5’-GCCTTCTCGGAACTTGCAGTGAAAGTCATCTATCTTTTCC-3’ and
primer 2: 5’-GGAAAAGATAGATGACTTTCACTGCAAGTTCCGAGAAGGC-3’ for
the p.Arg658*; FANCM c.5101 C > T primer 1: 5’-TTAAACAATGGTCC-
TATTGTTTGTTCTTCTTAACAGTGCTTGGGT-3’ and primer 2: 5’-ACCCAAG-
CACTGTTAAGAAGAACAAACAATAGGACCATTGTTTAA-3’ for the p.Gln1701*.
Generation of the lentiviral vector containing the FANCM:c.5791 C > T (p.
Arg1931*) and transduction of the EGF280 cells were already described.11
Expression of exogenous FANCM protein was achieved supplementing cell
culture medium with doxycycline (1 μg/ml, ﬁnal concentration). All the cell
lines used in this study were routinely checked for mycoplasma
contamination using the MycoAlert™ Mycoplasma Detection Kit (Lonza).
Western blot and mRNA expression studies
Cell lysis and western blot assays were performed as previously described.8
The following primary antibodies were used: mouse monoclonal anti-
FANCM antibody, clone CV5.1 diluted 1:100 (ref: MABC545, MERCK
Millipore), mouse monoclonal anti-Vinculin diluted 1:3000 (ref: ab18058,
abcam). Western blotting detection was achieved with LuminataTM
Classico (Millipore) (Vinculin) and LuminataForteTM (Millipore) (FANCM).
We used RT PCR to test the expression of the mutant FANCM:p.Arg658*.
Total RNA was extracted (RNeasy Mini Kit Qiagen) from the wtFANCM and
FANCM:p.Arg658* transduced EGF280 cell lines. Reverse transcription was
performed using High-Capacity RNA-to-cDNA Kit (Thermoﬁsher); a cDNA
region corresponding to the FANCM sequence containing the amino acid
(AA) position Arg658 was ampliﬁed by PCR using the forward: 5’-
AGTAACAGGCAGGTCCTTCA-3´and reverse: 5’-TGATCTTGCCACAGTCTCCA-
3’ primers. The 386 bp PCR products were then digested with TseI
restriction enzyme (New England Biolabs) for two hours at 65 °C and
analyzed by standard agarose gel electrophoresis.
Cell survival assay
The effect of the different FANCM variants on cell survival was measured
with a Sulforhodamine B (SRB) assay.21 One-thousand cells were seeded in
96-well plates and treated constantly with DEB or PARPi olaparib at the
indicated concentrations until untreated cells reached conﬂuency. Cell
monolayers were ﬁxed overnight at 4 °C with 75 μl of 20% trichloroacetic
acid (TCA). TCA was aspirated, and cells washed with tap water. Once dried,
50 μl of SRB was added to the wells and plates were incubated on a shaker
at room temperature for 30min. The excess of SRB dye was removed by
washing repeatedly with 1% acetic acid, the plates were dried for 20min,
and the protein-bound dye was dissolved in 10mM Tris for OD
determination at 492 nm using a microplate reader (Tecan Sunrise™,
Tecan Group Ltd. Männedorf, Switzerland). At least three independent
experiments were performed for each cell line and in each experiment, 12
wells were measured per concentration point. These results were
statistically analyzed using the Prism (GraphPad) software. Two-Way
ANOVA test was used for single comparisons between different cell lines
and statistical signiﬁcance was assessed with the Tukey’s range test. A P-
value < 0.05 was considered statistically signiﬁcant.
Chromosome fragility test
Chromosome fragility test was performed as previously described.11
Twenty-ﬁve metaphases were scored for chromosome breakages using the
Metafer Slide Scanning Platform from Metasystems. Results were graphed
as distributions of metaphases presenting 0, 1, and >1 chromatid break.
Statistical analysis was performed applying chi-squared test.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary
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